MXPA02001268A - Antagonistas de il-16. - Google Patents

Antagonistas de il-16.

Info

Publication number
MXPA02001268A
MXPA02001268A MXPA02001268A MXPA02001268A MXPA02001268A MX PA02001268 A MXPA02001268 A MX PA02001268A MX PA02001268 A MXPA02001268 A MX PA02001268A MX PA02001268 A MXPA02001268 A MX PA02001268A MX PA02001268 A MXPA02001268 A MX PA02001268A
Authority
MX
Mexico
Prior art keywords
present
peptides
antagonists
discoveries
terminus
Prior art date
Application number
MXPA02001268A
Other languages
English (en)
Spanish (es)
Inventor
David M Center
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of MXPA02001268A publication Critical patent/MXPA02001268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
MXPA02001268A 1999-08-05 2000-08-04 Antagonistas de il-16. MXPA02001268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/368,630 US6699466B1 (en) 1999-08-05 1999-08-05 IL-16 antagonist peptides and DNA encoding the peptides
PCT/US2000/021317 WO2001010893A2 (en) 1999-08-05 2000-08-04 Il-16 antagonists

Publications (1)

Publication Number Publication Date
MXPA02001268A true MXPA02001268A (es) 2003-09-10

Family

ID=23452058

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001268A MXPA02001268A (es) 1999-08-05 2000-08-04 Antagonistas de il-16.

Country Status (6)

Country Link
US (6) US6699466B1 (https=)
EP (1) EP1212363A2 (https=)
JP (1) JP2003507011A (https=)
CA (1) CA2378778C (https=)
MX (1) MXPA02001268A (https=)
WO (1) WO2001010893A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
AU2003213963A1 (en) * 2002-04-08 2003-10-27 The John P. Robarts Research Institute Method of treating or preventing autoimmune disease
FR2869528B1 (fr) * 2004-04-28 2007-02-02 Ldr Medical Prothese de disque intervertebral
WO2009129374A2 (en) * 2008-04-18 2009-10-22 Trustees Of Boston University Methods and compositions for preventing adhesion
DK2318020T3 (en) 2008-06-30 2015-11-30 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
SG10201913509YA (en) * 2016-04-28 2020-02-27 Nat Univ Singapore Therapeutic sall4 peptide
CN117860892B (zh) * 2023-12-26 2024-08-06 武汉大学中南医院 Il-16阳性神经元在调节恐惧消退记忆中的作用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
ES2320090T3 (es) * 1993-05-21 2009-05-19 Trustees Of Boston University Factor quimiotactico de linfocitos y usos del mismo.
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2216755A1 (en) * 1995-03-31 1996-10-03 Brian Lee Buckwalter Peptides with growth promotion properties
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
DE19649233A1 (de) * 1996-11-28 1998-06-04 Boehringer Mannheim Gmbh Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
JP2001520748A (ja) * 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
DE69837542T2 (de) * 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
AU2424399A (en) 1998-01-24 1999-08-09 Bundesrepublik Deutschland Mutants of il-16, processes for their production, and their use
EP1066047A4 (en) 1998-03-25 2004-10-13 Mayo Foundation For Medicaledu METHOD AND SUBSTANCES FOR TREATING FLAMMABLE DISEASES
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides

Also Published As

Publication number Publication date
US20030153504A1 (en) 2003-08-14
CA2378778A1 (en) 2001-02-15
US20100008936A1 (en) 2010-01-14
US20070031375A1 (en) 2007-02-08
WO2001010893A3 (en) 2001-08-16
US7608691B2 (en) 2009-10-27
JP2003507011A (ja) 2003-02-25
EP1212363A2 (en) 2002-06-12
WO2001010893A2 (en) 2001-02-15
CA2378778C (en) 2011-04-19
US7914778B2 (en) 2011-03-29
US20110207679A1 (en) 2011-08-25
US20120213790A1 (en) 2012-08-23
US7208149B2 (en) 2007-04-24
US6699466B1 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
ZA200107495B (en) N-cyanomethyl amides as protease inhibitors.
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
EP0769958A4 (en) INHIBITORS OF LEUKOCYTE ADHESION
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
WO2001079464A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
SE0002202D0 (sv) New peptides
MX2008009493A (es) Peptido novedoso y uso del mismo.
GB2367061A (en) Peptides
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
BG104267A (en) Aminoterminally incised rantes as haemokin antagonists
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
MXPA02001268A (es) Antagonistas de il-16.
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
WO2003097678A3 (en) Use of the repressor glxr for the synthesis of lysine in corynebacterium glutamicum
HK1046693A1 (zh) 用於免疫治疗的修饰的肽和拟肽
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
DE50002304D1 (en) Tyrosin- und tryptophanhaltige peptide als antioxidantien
EP0858808A3 (en) Peptides for use in wound treatment